Bortezomib-pinanediol

• UNSPSC Description:

  Bortezomib-pinanediol is a proteasome inhibitor and a prodrug of Bortezomib (HY-10227). Bortezomib-pinanediol inhibits cell growth and can be used for study of multiple myeloma[1].

• Target Antigen:

  Proteasome

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bortezomib-pinanediol.html

• Smiles:

  O=C(C1=NC=CN=C1)N[C@@H](CC2=CC=CC=C2)C(N[C@H](B3O[C@@]4([H])[C@@]([C@](C5)([H])C(C)(C)[C@]5([H])C4)(C)O3)CC(C)C)=O

• Molecular Weight:

  518.46

• References & Citations:

  [1]Gu Z, et al. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma. Acta Biomater. 2018;80:288-295.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  205393-22-2